{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:34:40Z","timestamp":1780965280022,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,6,8]],"date-time":"2007-06-08T00:00:00Z","timestamp":1181260800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1007\/s11102-007-0048-4","type":"journal-article","created":{"date-parts":[[2007,6,7]],"date-time":"2007-06-07T15:14:13Z","timestamp":1181229253000},"page":"261-266","source":"Crossref","is-referenced-by-count":14,"title":["Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI)"],"prefix":"10.1007","volume":"10","author":[{"given":"Alireza M.","family":"Manuchehri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thozhukat","family":"Sathyapalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Lowry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay W.","family":"Turnbull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Rowland-Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Atkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,6,8]]},"reference":[{"key":"48_CR1","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1159\/000126575","volume":"58","author":"SK Park","year":"1993","unstructured":"Park SK, Keenan MW, Selmanoff M (1993) Graded hyperprolactinemia first suppresses LH pulse frequency and then pulse amplitude in castrated male rats. Neuroendocrinology 58:448\u2013453","journal-title":"Neuroendocrinology"},{"key":"48_CR2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/beem.1999.0030","volume":"13","author":"J Webster","year":"1999","unstructured":"Webster J (1999) Clinical management of prolactinomas. Baillieres Best Pract Res Clin Endocrinol Metab 13:395\u2013408","journal-title":"Baillieres Best Pract Res Clin Endocrinol Metab"},{"key":"48_CR3","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1210\/jcem-55-6-1178","volume":"55","author":"GT Tindall","year":"1982","unstructured":"Tindall GT, Kovacs K, Horvath E, Thorner MO (1982) Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study. J Clin Endocrinol Metab 55:1178\u20131183","journal-title":"J Clin Endocrinol Metab"},{"key":"48_CR4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1227\/00006123-198202000-00012","volume":"10","author":"SS Rengachary","year":"1982","unstructured":"Rengachary SS, Tomita T, Jefferies BF, Watanabe I (1982) Structural changes in human pituitary tumor after bromocriptine therapy. Neurosurgery 10:242\u2013251","journal-title":"Neurosurgery"},{"key":"48_CR5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/BF03350542","volume":"5","author":"M Nissim","year":"1982","unstructured":"Nissim M, Ambrosi B, Bernasconi V et al (1982) Bromocriptine treatment of macroprolactinomas: studies on the time course of tumor shrinkage and morphology. J Endocrinol Invest 5:409\u2013415","journal-title":"J Endocrinol Invest"},{"key":"48_CR6","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/BF01971131","volume":"39","author":"AM Landolt","year":"1983","unstructured":"Landolt AM, Minder H, Osterwalder V, Landolt TA (1983) Bromocriptine reduces the size of cells in prolactin-secreting pituitary adenomas. Experientia 39:625\u2013626","journal-title":"Experientia"},{"key":"48_CR7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1152\/physrev.1998.78.1.189","volume":"78","author":"C Missale","year":"1998","unstructured":"Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78:189\u2013225","journal-title":"Physiol Rev"},{"key":"48_CR8","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1210\/edrv-13-2-220","volume":"13","author":"JS Bevan","year":"1992","unstructured":"Bevan JS, Webster J, Burke CW, Scanlon MF (1992) Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 13:220\u2013240","journal-title":"Endocr Rev"},{"key":"48_CR9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/j.1600-0412.1998.770301.x","volume":"77","author":"P Conner","year":"1998","unstructured":"Conner P, Fried G (1998) Hyperprolactinemia; etiology, diagnosis and treatment alternatives. Acta Obstet Gynecol Scand 77:249\u2013262","journal-title":"Acta Obstet Gynecol Scand"},{"key":"48_CR10","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1210\/jcem-69-3-500","volume":"69","author":"I Pellegrini","year":"1989","unstructured":"Pellegrini I, Rasolonjanahary R, Gunz G et al (1989) Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 69:500\u2013509","journal-title":"J Clin Endocrinol Metab"},{"key":"48_CR11","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1159\/000126764","volume":"60","author":"L Caccavelli","year":"1994","unstructured":"Caccavelli L, Feron F, Morange I et al (1994) Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 60:314\u2013322","journal-title":"Neuroendocrinology"},{"key":"48_CR12","doi-asserted-by":"crossref","first-page":"573","DOI":"10.5414\/CPP40573","volume":"40","author":"K Mross","year":"2002","unstructured":"Mross K, Fuxius S, Drevs J (2002) Serial measurements of pharmacokinetics, DCE-MRI, blood flow, PET and biomarkers in serum\/plasma\u2014what is a useful tool in clinical studies of anti-angiogenic drugs? Int J Clin Pharmacol Ther 40:573\u2013574","journal-title":"Int J Clin Pharmacol Ther"},{"key":"48_CR13","doi-asserted-by":"crossref","first-page":"600","DOI":"10.5414\/CPP41600","volume":"41","author":"U Zirrgiebel","year":"2003","unstructured":"Zirrgiebel U, Drevs J (2003) Surrogate marker in clinical studies with anti-angiogenic drugs. Int J Clin Pharmacol Ther 41:600\u2013602","journal-title":"Int J Clin Pharmacol Ther"},{"key":"48_CR14","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/00004728-199107000-00018","volume":"15","author":"G Brix","year":"1991","unstructured":"Brix G, Semmler W, Port R, Schad LR, Layer G, Lorenz WJ (1991) Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 15:621\u2013628","journal-title":"J Comput Assist Tomogr"},{"key":"48_CR15","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/mrm.1910320514","volume":"32","author":"DL Buckley","year":"1994","unstructured":"Buckley DL, Kerslake RW, Blackband SJ, Horsman A (1994) Quantitative analysis of multi-slice Gd-DTPA enhanced dynamic MR images using an automated simplex minimization procedure. Magn Reson Med 32:646\u2013651","journal-title":"Magn Reson Med"},{"key":"48_CR16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/jmri.1880070113","volume":"7","author":"PS Tofts","year":"1997","unstructured":"Tofts PS (1997) Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 7:91\u2013101","journal-title":"J Magn Reson Imaging"},{"key":"48_CR17","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/mrm.1910310516","volume":"31","author":"K Hittmair","year":"1994","unstructured":"Hittmair K, Gomiscek G, Langenberger K, Recht M, Imhof H, Kramer J (1994) Method for the quantitative assessment of contrast agent uptake in dynamic contrast-enhanced MRI. Magn Reson Med 31:567\u2013571","journal-title":"Magn Reson Med"},{"key":"48_CR18","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1210\/jcem.85.3.6485","volume":"85","author":"HE Turner","year":"2000","unstructured":"Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL, Wass JA (2000) Angiogenesis in pituitary adenomas and the normal pituitary gland. J Clin Endocrinol Metab 85:1159\u20131162","journal-title":"J Clin Endocrinol Metab"},{"key":"48_CR19","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1021\/ol048084u","volume":"6","author":"A Dirksen","year":"2004","unstructured":"Dirksen A, Langereis S, de Waal BF et al (2004) Design and synthesis of a bimodal target-specific contrast agent for angiogenesis. Org Lett 6:4857\u20134860","journal-title":"Org Lett"},{"key":"48_CR20","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/87895","volume":"7","author":"S Basu","year":"2001","unstructured":"Basu S, Nagy JA, Pal S et al (2001) The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor\/vascular endothelial growth factor. Nat Med 7:569\u2013574","journal-title":"Nat Med"},{"key":"48_CR21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF03345118","volume":"26","author":"P Viacava","year":"2003","unstructured":"Viacava P, Gasperi M, Acerbi G et al (2003) Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas. J Endocrinol Invest 26:23\u201328","journal-title":"J Endocrinol Invest"},{"key":"48_CR22","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1210\/jc.2002-020309","volume":"87","author":"CJ McCabe","year":"2002","unstructured":"McCabe CJ, Boelaert K, Tannahill LA et al (2002) Vascular endothelial growth factor, its receptor KDR\/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 87:4238\u20134244","journal-title":"J Clin Endocrinol Metab"},{"key":"48_CR23","first-page":"639","volume":"17","author":"N Ben-Jonathan","year":"1996","unstructured":"Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW (1996) Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev 17:639\u2013669","journal-title":"Endocr Rev"},{"key":"48_CR24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0010-7824(98)00069-9","volume":"58","author":"G Testa","year":"1998","unstructured":"Testa G, Vegetti W, Motta T et al (1998) Two-year treatment with oral contraceptives in hyperprolactinemic patients. Contraception 58:69\u201373","journal-title":"Contraception"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-007-0048-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11102-007-0048-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-007-0048-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T21:14:07Z","timestamp":1587590047000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11102-007-0048-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,8]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["48"],"URL":"https:\/\/doi.org\/10.1007\/s11102-007-0048-4","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,8]]}}}